Critical Outcome T Com Npv (NASDAQ:COTQF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.

According to Zacks, “Critical Outcome Technologies Inc. is a biopharmaceutical company which focuses on treatment of cancer. The company’s product consists of COTI-2, a novel p53-dependent mechanism of action with selective and potent anti-cancer activity. Its artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing. Critical Outcome Technologies Inc. is based in London, Canada. “

Shares of Critical Outcome T Com Npv (NASDAQ:COTQF) traded down 9.58% on Tuesday, reaching $0.40. 2,200 shares of the company were exchanged. The stock’s market capitalization is $59.49 million. Critical Outcome T Com Npv has a 12-month low of $0.16 and a 12-month high of $0.69. The firm has a 50 day moving average price of $0.25 and a 200-day moving average price of $0.22.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Lowers Critical Outcome T Com Npv (COTQF) to Sell” was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this news story on another site, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be read at

5 Day Chart for NASDAQ:COTQF

Receive News & Stock Ratings for Critical Outcome T Com Npv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Critical Outcome T Com Npv and related stocks with our FREE daily email newsletter.